HealthEquity shares fell 10.2% following the release of its 2027 guidance, which projected revenue of $1.38–$1.41 billion and adjusted EBITDA margins of 43.8–44.3%. While this outlook fell slightly below some analyst expectations, management emphasized that the projections reflect disciplined investments in technology and customer acquisition designed to sustain long-term growth. Trading volume on the drop day exceeded the 30-day average by 40%, underscoring the market’s surprise at the company’s more conservative near-term targets.

HealthEquity’s hallmark health savings account (HSA) platform now serves over 17 million accounts and manages $34 billion in assets, marking year-over-year growth of 12% in account count and 18% in assets under management. The company reported 9% quarterly revenue growth in Q4, driven by higher contribution levels per account and increased adoption among employer groups. Attrition rates remain low at 4.5%, reflecting robust member engagement through digital tools such as the mobile app, which recorded a 25% increase in daily active users over the past 12 months.

Since Scott Cutler’s appointment as CEO in early 2023, HealthEquity has executed a disciplined three-pillar playbook: modernizing its core technology stack, deepening client engagement, and expanding service offerings. Over the past year, the company deployed a new data analytics engine to personalize member communications, resulting in a 15% lift in contribution reminders opened. It also launched integrated COBRA and FSA modules that have been adopted by more than 600 midsized employers, adding incremental recurring revenue streams.

Analysts at Crude Value Insights reaffirmed their buy recommendation, citing HealthEquity’s predictable free cash flow generation and expanding EBITDA margin profile. The company converted 95% of operating earnings to free cash flow in the last fiscal year, enabling continued share repurchases and debt reduction. With net leverage at 1.8x EBITDA—down from 2.2x two years ago—management has flexibility to pursue strategic M&A opportunities in adjacent benefits technology markets, further underpinning the bullish investment thesis.